Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 919-932

  Wilson, Claire H ^a,b   Abbott, Catherine A ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

Author keywords

Breast cancer; Dipeptidyl peptidase; DP4; DP8; DP9; Epithelial ovarian cancer; Expression

Indexed keywords

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; MESSENGER RNA; PROLYL ENDOPEPTIDASE; SEPRASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CELL PERMEABILIZATION; CELL STRAIN MCF 7; ENZYME ACTIVITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; UBIQUITINATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DIPEPTIDASES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; FEMALE; GELATINASES; GENE EXPRESSION PROFILING; HEK293 CELLS; HELA CELLS; HUMANS; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES;

EID: 84865031128     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1522     Document Type: Article

References (80)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Cho KR and Shih Ie M: Ovarian cancer. Annu Rev Pathol 4: 287-313, 2009.
3. Schnitt SJ: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 23 (Suppl 2): S60-S64, 2010.
4. Kurman RJ and Shih Ie M: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151-160, 2008. (Pubitemid 351450677)
5. Lambeir AM, Durinx C, Scharpe S and De Meester I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40: 209-294, 2003. (Pubitemid 36775376)
6. Bjelke JR, Christensen J, Nielsen PF, Branner S, Kanstrup AB, Wagtmann N and Rasmussen HB: Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 396: 391-399, 2006. (Pubitemid 43837255)
7. Ajami K, Pitman MR, Wilson CH, Park J, Menz RI, Starr AE, Cox JH, Abbott CA, Overall CM and Gorrell MD: Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 582: 819-825, 2008.
8. Keane FM, Nadvi NA, Yao TW and Gorrell MD: Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J 278: 1316-1332, 2011.
9. Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A and Grouzmann E: Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 166: 433-442, 2005. (Pubitemid 40189040)
10. Barbieri F, Bajetto A and Florio T: Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol 2010: 426956, 2010.
11. Ali S and Lazennec G: Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26: 401-420, 2007. (Pubitemid 350115103)
12. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4: 540-550, 2004.
13. Mentlein R: Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 85: 9-24, 1999.
14. Sun YX, Pedersen EA, Shiozawa Y, Havens AM, Jung Y, Wang J, Pienta KJ and Taichman RS: CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis 25: 765-776, 2008.
15. Arscott WT, La Bauve AE, May V and Wesley UV: Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene 28: 479-491, 2009.
16. Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, Jeha D, Hanafy J, Lee CK, Sun J, Izycka-Swiezczewska E, Toretsky JA and Kitlinska J: Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors. J Biol Chem 286: 27494-27505, 2011.
17. Yu DM, Wang XM, McCaughan GW and Gorrell MD: Extra-enzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J 273: 2447-2460, 2006. (Pubitemid 43736658)
18. Wang XM, Yu DM, McCaughan GW and Gorrell MD: Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 42: 935-945, 2005. (Pubitemid 41401132)
19. Sulda ML, Abbott CA and Hildebrandt M: DPIV/CD26 and FAP in cancer: a tale of contradictions. Adv Exp Med Biol 575: 197-206, 2006.
20. Johnson RC, Zhu D, Augustin-Voss HG and Pauli BU: Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. J Cell Biol 121: 1423-1432, 1993. (Pubitemid 23174557)
21. Cheng HC, Abdel-Ghany M, Elble RC and Pauli BU: Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem 273: 24207-24215, 1998. (Pubitemid 28435768)
22. Cheng HC, Abdel-Ghany M, Zhang S and Pauli BU: Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer? Clin Exp Metastasis 17: 609-615, 1999. (Pubitemid 30337135)
23. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K and Mizutani S: Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 62: 2753-2757, 2002. (Pubitemid 34525756)
24. Kajiyama H, Shibata K, Ino K, Mizutani S, Nawa A and Kikkawa F: The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Sci 101: 347-354, 2010.
25. Garin-Chesa P, Old LJ and Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87: 7235-7239, 1990.
26. Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G and Chen WT: Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res 66: 9977-9985, 2006. (Pubitemid 44672050)
27. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330: 827-830, 2010.
28. Kelly T, Kechelava S, Rozypal TL, West KW and Korourian S: Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol 11: 855-863, 1998. (Pubitemid 28440882)
29. Ariga N, Sato E, Ohuchi N, Nagura H and Ohtani H: Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 95: 67-72, 2001.
30. Goodman JD, Rozypal TL and Kelly T: Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis 20: 459-470, 2003. (Pubitemid 37108433)
31. Huang Y, Wang S and Kelly T: Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 64: 2712-2716, 2004. (Pubitemid 38500606)
32. Kennedy A, Dong H, Chen D and Chen WT: Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer 124: 27-35, 2009.
33. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW and Gorrell MD: Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267: 6140-6150, 2000.
34. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW and Gorrell MD: The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 277: 1126-1144, 2010.
35. Dubois V, Van Ginneken C, De Cock H, Lambeir AM, Van der Veken P, Augustyns K, Chen X, Scharpe S and De Meester I: Enzyme activity and immunohistochemical localization of dipeptidyl Peptidase 8 and 9 in male reproductive tissues. J Histochem Cytochem 57: 531-541, 2009.
36. Yao TW, Kim WS, Yu DM, Sharbeen G, McCaughan GW, Choi KY, Xia P and Gorrell MD: A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res 9: 948-959, 2011.
37. Sulda ML, Abbott CA, Macardle PJ, Hall RK and Kuss BJ: Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia. Cancer Biol Ther 10: 180-189, 2010.
38. Yu DM, Ajami K, Gall MG, Park J, Lee CS, Evans KA, McLaughlin EA, Pitman MR, Abbott CA, McCaughan GW and Gorrell MD: The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 57: 1025-1040, 2009.
39. Stremenova J, Mares V, Lisa V, Hilser M, Krepela E, Vanickova Z, Syrucek M, Soula O and Sedo A: Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas. Int J Oncol 36: 351-358, 2010.
40. Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, Vanickova Z, Lisa V, Yea C and Sedo A: Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int J Oncol 31: 785-792, 2007.
41. Soule HD, Vazguez J, Long A, Albert S and Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
42. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP and Johnson PH: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61: 5168-5178, 2001. (Pubitemid 32681550)
43. Crow MJ, Grant G, Provenzale JM and Wax A: Molecular imaging and quantitative measurement of epidermal growth factor receptor expression in live cancer cells using immunolabeled gold nanoparticles. AJR Am J Roentgenol 192: 1021-1028, 2009.
44. Lau KM, Mok SC and Ho SM: Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96: 5722-5727, 1999. (Pubitemid 29234685)
45. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB and Koeffler HP: 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104: 2701-2708, 2005. (Pubitemid 41798280)
46. Xu F, Yu Y, Le XF, Boyer C, Mills GB and Bast RC: The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5: 3653-3660, 1999.
47. Hua W, Christianson T, Rougeot C, Rochefort H and Clinton GM: SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 55: 279-289, 1995. (Pubitemid 26022200)
48. Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M and Deisseroth AB: Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 89: 1271-1276, 1997. (Pubitemid 27371947)
49. Monje P and Boland R: Expression and cellular localization of naturally occurring beta estrogen receptors in uterine and mammary cell lines. J Cell Biochem 86: 136-144, 2002.
50. Lossos IS, Czerwinski DK, Wechser MA and Levy R: Optimi-zation of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 17: 789-795, 2003. (Pubitemid 36519378)
51. Maes MB, Dubois V, Brandt I, Lambeir AM, Van der Veken P, Augustyns K, Cheng JD, Chen X, Scharpe S and De Meester I: Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukocyte Biol 81: 1252-1257, 2007. (Pubitemid 46702044)
52. Abbott CA and Gorrell MD: The family of CD26/DPIV related ectopeptidases. In: Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology. Langner J and Ansorge S (eds). Kluwer/Plenum, New York, pp171-195, 2002.
53. Balaziova E, Busek P, Stremenova J, Sromova L, Krepela E, Lizcova L and Sedo A: Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-alpha in transformed astrocytic cells. Mol Cell Biochem 354: 283-289, 2011.
54. Ajami K, Abbott CA, McCaughan GW and Gorrell MD: Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 1679: 18-28, 2004. (Pubitemid 38881620)
55. Pitman MR, Menz RI and Abbott CA: Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8). Biol Chem 391: 959-972, 2010.
56. Bank U, Heimburg A, Wohlfarth A, Koch G, Nordhoff K, Julius H, Helmuth M, Breyer D, Reinhold D, Tager M and Ansorge S: Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects. Biol Chem 392: 169-187, 2011.
57. Ansorge S, Nordhoff K, Bank U, Heimburg A, Julius H, Breyer D, Thielitz A, Reinhold D and Tager M: Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem 392: 153-168, 2011.
58. Kikkawa F, Kajiyama H, Ino K, Shibata K and Mizutani S: Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer 105: 779-783, 2003. (Pubitemid 36706100)
59. Huang Y, Simms AE, Mazur A, Wang S, Leon NR, Jones B, Aziz N and Kelly T: Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 28: 567-579, 2011.
60. Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, Zhang Y, Kraus ML, Salakian S, Sridhar V, Wijnands R and Tennant MG: Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 280: 19441-19444, 2005. (Pubitemid 41379462)
61. Chiravuri M, Agarraberes F, Mathieu SL, Lee H and Huber BT: Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol 165: 5695-5702, 2000.
62. Tang HK, Tang HY, Hsu SC, Chu YR, Chien CH, Shu CH and Chen X: Biochemical properties and expression profile of human prolyl dipeptidase DPP9. Arch Biochem Biophys 485: 120-127, 2009.
63. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT and Thornberry NA: Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 371: 525-532, 2003. (Pubitemid 36547636)
64. Maes MB, Martinet W, Schrijvers DM, Van der Veken P, De Meyer GR, Augustyns K, Lambeir AM, Scharpe S and De Meester I: Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol 72: 70-79, 2006. (Pubitemid 43795343)
65. Danilova O, Li B, Szardenings AK, Huber BT and Rosenblum JS: Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorg Med Chem Lett 17: 507-510, 2007. (Pubitemid 46073735)
66. Hui M and Hui KS: A novel aminopeptidase with highest preference for lysine. Neurochem Res 31: 95-102, 2006. (Pubitemid 43234550)
67. Claperon C, Banegas-Font I, Iturrioz X, Rozenfeld R, Maigret B and Llorens-Cortes C: Identification of threonine 348 as a residue involved in aminopeptidase A substrate specificity. J Biol Chem 284: 10618-10626, 2009.
68. Fukasawa KM, Hirose J, Hata T and Ono Y: Aspartic acid 405 contributes to the substrate specificity of aminopeptidase B. Biochemistry 45: 11425-11431, 2006. (Pubitemid 44453990)
69. Drag M, Bogyo M, Ellman JA and Salvesen GS: Aminopeptidase fingerprints, an integrated approach for identification of good substrates and optimal inhibitors. J Biol Chem 285: 3310-3318, 2010.
70. Tenorio-Laranga J, Venalainen JI, Mannisto PT and Garcia-Horsman JA: Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J 275: 4415-4427, 2008.
71. Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W and Wolf BB: Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett 580: 1581-1586, 2006. (Pubitemid 43290354)
72. Cheng JQ, Lindsley CW, Cheng GZ, Yang H and Nicosia SV: The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482-7492, 2005. (Pubitemid 41637988)
73. Hernandez-Aya LF and Gonzalez-Angulo AM: Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16: 404-414, 2011.
74. Zagouri F, Dimopoulos MA, Bournakis E and Papadimitriou CA: Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol 31: 268-277, 2010.
75. Mazzoletti M and Broggini M: PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem 17: 4433-4447, 2010.
76. Dickson RB, Thompson EW and Lippman ME: Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J Steroid Biochem Mol Biol 37: 305-316, 1990.
77. Kim HJ, Cui X, Hilsenbeck SG and Lee AV: Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 12: S1013-S1018, 2006.
78. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282, 2006.
79. Oakman C, Viale G and Di Leo A: Management of triple negative breast cancer. Breast 19: 312-321, 2010.
80. Rao BR, Slotman BJ, Geldof AA and Dinjens WN: Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer. Int J Gynecol Pathol 9: 47-54, 1990. (Pubitemid 20067455)